BT and Schrödinger, Inc. have announced that the two companies are now working together to accelerate the process of drug discovery and development using the BT for Life Sciences cloud platform and Schrödinger?s powerful scientific software applications.
As part of the joint initiative, Schrödinger becomes a Strategic Member of the BT for Life Sciences partner ecosystem, helping provide research solutions to scientists on a global basis. Schrödinger?s software tools will be integrated into BT for Life Sciences as part of BT?s R&D Workbench environment. Built on the BT Cloud Compute platform and unveiled at the 10th Annual BioIT World meeting last year, BT for Life Sciences is the first cloud service designed to enable collaboration within the life sciences industry for increased productivity in discovery, research and development.
One of Schrödinger?s key applications, hosted Seurat, will soon be available on the BT Cloud Compute Platform. This application contains tools that help researchers in the discovery and optimization of drug research and provides a means for sharing real-time analysis across the organization. Using the BT platform, Schrödinger can easily integrate data and scientific business processes, enhancing the early discovery process so that ultimately better compounds can be brought to the clinic faster.
Because BT for Life Sciences was developed as a secure and segregated platform for scientists, it will enable Schrödinger to work with major pharmaceutical companies and other biotech organizations that need faster and more innovative approaches to drug discovery and development. In the past, researchers would typically provide the IT department with the requirements for each in silico experiment, which could mean a delay in research and discovery as the equipment was purchased and the platform built. Using BT?s cloud services for Life Sciences, Schrödinger can now offer their applications quickly and easily with a click-to-launch approach that uses secure, compliant, and scalable cloud computing, storage and databanks, in order to process demanding scientific analysis.
Dr. Ramy Farid, Schrödinger?s president, said: ?Integrating Schrödinger?s scientific breakthroughs with BT?s cloud services takes us one step closer in our mission to empower researchers to improve human health and quality of life through advanced computational techniques. We believe that providing our applications in BT?s cloud environment could transform the way chemists discover and design compounds and drugs.?
Bas Burger, president of Pharmaceutical & Chemical for BT Global Services, said: ?Drawing on BT?s years of experience and expertise in the pharmaceutical industry, our cloud-based service can help accelerate the process of R&D for companies like Schrödinger. Our goal is to provide the best solutions to our global pharmaceutical customers that will enable them to meet their mission.?
Hvis du har sp?rsm?l kan du kontakte:
Marcus Forsgren, Bite Communications
+46 76 319 88 23
BT er en av verdens ledende leverand?rer av kommunikasjonstjenester og -l?sninger, og betjener kunder i mer enn 170 land. Hovedaktivitetene inkluderer leveranse av globale nettverksbaserte IT-tjenester; lokale, nasjonale og internasjonale telekommunikasjonstjenester for selskapets kunder til bruk hjemme, p? arbeid og p? farten; bredb?nd- og internettprodukter og -tjenester samt konvergerende fastlinje/mobile produkter og tjenester. BT best?r hovedsakelig av fire forretningsomr?der: BT Global Services, BT Retail, BT Wholesale og Openreach.
I finans?ret som sluttet 31. mars 2012, var BT Groups inntekter ?18 897 millioner med et resultat f?r skatt p? ?2 445 millioner.
British Telecommunications plc (BT) er et heleid datterselskap av BT Group plc og omfatter nesten alle forretninger og eiendeler i BT Group. BT Group plc er notert p? b?rsene i London og New York. G? til www.btplc.com hvis du vil ha mer informasjon.